In vivo monitoring of parathyroid hormone treatment after myocardial infarction in mice with [68Ga]annexin A5 and [18F]fluorodeoxyglucose positron emission tomography by Lehner, Sebastian et al.
RESEARCH ARTICLE
In Vivo Monitoring of Parathyroid Hormone Treatment
after Myocardial Infarction in Mice with [68Ga]Annexin A5
and [18F]Fluorodeoxyglucose Positron Emission
Tomography
Sebastian Lehner, Andrei Todica, Yordan Vanchev, Christopher Uebleis, Hao Wang, Tanja Herrler, Carmen Wa¨ngler,
Paul Cumming, Guido Bo¨ning, Wolfgang M. Franz, Peter Bartenstein, Marcus Hacker, and Stefan Brunner
Abstract
[68Ga]Annexin A5 positron emission tomography (PET) reveals the externalization of phosphatidylserine as a surrogate marker for
apoptosis. We tested this technique for therapy monitoring in a murine model of myocardial infarction (MI) including parathyroid
hormone (PTH) treatment. MI was induced in mice, and they were assigned to the saline or the PTH group. On day 2, they received
[68Ga]annexin A5 PET or histofluorescence TUNEL staining. Mice had 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-PET examinations on
days 6 and 30 for calculation of the left ventricular ejection fraction and infarct area. [68Ga]Annexin A5 uptake was 7.4 6 1.3 %ID/g
within the infarction for the controls and 4.5 6 1.9 %ID/g for the PTH group (p 5 .013). TUNEL staining revealed significantly more
apoptotic cells in the infarct area on day 2 in the controls (64 6 9%) compared to the treatment group (52 6 4%; p 5 .045). FDG-PET
revealed a significant decrease in infarct size in the treatment group and an increase in the controls. Examinations of left ventricular
ejection fraction on days 6 and 30 did not reveal treatment effects. [68Ga]Annexin A5 PET can detect the effects of PTH treatment as a
marker of apoptosis 2 days after MI; ex vivo examination confirmed significant rescue of myocardiocytes. FDG-PET showed a small
but significant reduction in infarct size but no functional improvement.
A NIMAL STUDIES have suggested that parathyroidhormone (PTH) treatment after myocardial infarction
(MI) shows beneficial effects on infarct size, left ventricular
function, and cardiac remodeling and in general attenuates
the progression of ischemic cardiomyopathy.1,2 Several
mechanisms potentially mediating these effects of PTH have
been proposed. First, PTH is known to induce arterial
vasodilation by means of a receptor activation evoking
intracellular cyclic adenosine monophosphate (cAMP)
production.1,2 This pathway plausibly exerts beneficial effects
on the perfusion of ischemically afflicted myocardium.
Second, PTH induces the mobilization of progenitor cells
from the bone marrow into the peripheral blood.3 Third,
PTH increases plasma levels of cardiac stromal cell–derived
factor 1 (SDF-1), a chemokine facilitating the homing of stem
cells into the ischemic heart by activation of chemokine
receptor type 4 (CXCR4) (SDF-1/CXCR4 axis).4 These effects
lead to increased myocardial perfusion, neovascularization,
and enhanced cell survival and regeneration, ultimately
resulting in less apoptosis and cardiac remodeling and
improved postinfarct cardiac function.1
Serial examinations by positron emission tomography
(PET) enable serial in vivo molecular imaging of
myocardial survival and viability in small-animal infarct
models. PET with the glucose analogue 2-deoxy-2-
[18F]fluoro-D-glucose (FDG-PET) gives quantitative infor-
mation about the viability and the function of damaged
myocardium in vivo.5 Furthermore, we recently reported
that PET with [68Ga]annexin A5 serves to visualize and
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quantify phosphatidylserine externalization in the area
at risk after myocardial ischemia6; the binding of
[68Ga]annexin A5 to externalized phospholipids is con-
sidered a surrogate marker for myocardial apoptosis.
Based on our earlier findings with FDG and annexin
PET, we hypothesized that the myocardial viability and
externalization of phosphatidylserine on day 2 after MI
correlate with the long-term outcome.
Methods
Animal Model of Coronary Occlusion and PTH
Treatment
Experimental protocols were approved by the regional
governmental commission of animal protection (Regierung
von Oberbayern, Germany) and were performed in accor-
dance with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health.7
Male C57BL6/N mice were used in this study. For the
operation, mice were anesthetized with ketamine 70 mg/kg
body weight and xylazine 15 mg/kg body weight. For imaging,
mice were anesthetized with 1.5% isoflurane delivered in 1.2
liters O2/min by means of mechanical ventilation. The body
temperature was continuously monitored with a rectal probe
and maintained at an appropriate level with a heating lamp.
On induction of deep anesthesia, the heart was exposed by left
lateral thoracotomy as described previously by our group.6
Using a small needle, a suture (8-0 polypropylene) was placed
about the proximal portion of the left anterior descending
(LAD) artery, which was then ligated. The occlusion of the
vessel induced an MI, which was visually verified by the paling
of the tissue. After completion of the surgical procedure, the
animals were returned to their cages and left to recover.
Administration of PTH
The infarcted C57BL6/N mice were randomly assigned to
the treatment or the control group. The treatment group
received PTH (80 mg/kg/day) as an intraperitoneal injection
over 6 consecutive days. The PTH treatment was initiated
immediately after the infarction. The control group received
saline solution (0.9% NaCl) over 6 consecutive days in the
same manner as the treatment group. This approach was
previously described by Brunner and colleagues.2
In Vivo PET Imaging
[68Ga]Annexin A5 PET scanning was performed on day 2
after MI using a dedicated small-animal PET scanner
(Inveon Dedicated PET, Preclinical Solutions, Siemens
Healthcare Molecular Imaging, Knoxville, TN) (n 5 5 in
the treatment group, n 5 7 in the control group). For
labeling annexin A5 with [68Ga], a kit-like labeling technique
was applied, yielding a specific activity of 20 to 45 GBq/mol,
as described previously.6,8 After induction of anesthesia with
1.5% isoflurane, mice received an intravenous catheter into a
tail vein. Subsequently, 15 MBq [68Ga]annexin A5 was
injected in a volume of 150 mL, and the catheter was flushed
with 50 mL saline solution. Animals were placed in the
aperture of the tomograph, and a list-mode acquisition was
obtained in three-dimensional (3D) mode 60 to 90 minutes
after tracer injection. Emission recordings were followed by a
transmission scan with an external [57Co] point source for
scatter and attenuation correction. Animals were then taken
back to their cages to recover.
On days 6 and 30 after MI, animals were anesthetized
and catheterized as above; 20 MBq of FDG was injected
into a tail vein in a volume of 150 mL (n 5 13 in the
treatment group, n 5 10 in the control group), and the
catheter was flushed with 50 mL saline solution. Animals
were placed in the aperture of the tomograph, and a list-
mode acquisition was obtained in 3D mode 30 to 45
minutes after FDG injection, followed by an attenuation
scan as above. At the end of the last scan, the animals were
sacrificed by cervical dislocation while still under anesthe-
sia without regaining consciousness.
All PET data were processed with an Inveon Acquisition
Workplace (Siemens Medical Solutions, Knoxville, TN). The
[68Ga]annexin A5 scan was statically framed and iteratively
reconstructed using ordered subset expectation maximiza-
tion (OSEM) 3D (four iterations) and maximum a posteriori
(MAP) (32 iterations) image reconstruction algorithms. The
final images consisted of a 256 3 256 matrix (159 slices,
thickness of 0.796 mm, resulting in a voxel size of 0.15 mL)
with a zoom factor of 100% and a b of 0.15, as previously
established by our group.6 The FDG data were statically
framed and likewise reconstructed with the OSEM 3D (4
iterations) and fastMAP (32 iterations) image reconstruction
algorithms. The electrocardiogram (ECG)-gated FDG data
were divided into 16 equal intervals and iteratively
reconstructed using OSEM 3D (four iterations) and MAP
(32 iterations), as previously described by our group.9 All
PET data were normalized and corrected for randoms, dead
time and decay, and attenuation (Figure 1). Right after the
PET scan, the accuracy of the ECG trigger signals in the list-
mode data were verified using in-house software pro-
grammed in MATLAB (The Mathworks, Natick, MA) and
in C programming language, and erroneous trigger events
were removed as previously described.10
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PET Image Analysis
PET images were analyzed using an Inveon Research
Workplace (Siemens Medical Solutions). For the correct
allocation of the annexin A5 uptake to the area of infarction
and to the healthy myocardium, the day 6 FDG scan was
applied as a metabolic and anatomic landmark. An
automated volumetric software fusion algorithm was used
to ensure the greatest approximation between the annexin
and the FDG-PET scan. The results were verified visually, and
the remaining incongruities were eliminated manually.
[68Ga]Annexin A5 images were then analyzed by drawing
standard volumes of interest (VOI) with a size of 1.3 mL
around the region of peak tracer uptake within the area of
infarction (LAD artery perfusion territory) and within the
healthy myocardium as a control reference. We were careful
to avoid spill-over activity from the adjacent liver. The
correct VOI placement was verified in axial, coronal, and
sagittal projections. The mean radioactivity concentration
was quantified as the percentage of the injected dose per gram
(%ID/g), as previously described.6 Polar maps of the annexin
uptake were calculated with Munich Heart (Stefan Nekolla,
Technical University of Munich, Munich, Germany).
FDG images were analyzed using QPS 2012 and QGS
2012 software packages (Research Edition, PET Processing
plugin, Cedars-Sinai, Los Angeles, CA). For the calculation
of the infarct size, polar maps of the left ventricular FDG
uptake were created using QPS 2012. The polar maps were
then compared to a normative database consisting of
gender- and age-matched animals. In brief, by calculating
the extent of impaired glucose metabolism and the severity
of impaired glucose metabolism, expressed in units of
standard deviations from the normative data, the infarct size
was calculated as the percentage of the left ventricular
surface area. This approach is based on the method used by
Slomka and colleagues for perfusion data.11 In addition,
ECG-gated FDG images were exported as DICOM files and
loaded into QGS 2012. An automated wall recognition
algorithm was applied to delineate left ventricular contours,
and the left ventricular ejection fraction (LVEF) was
calculated as described by Brunner and colleagues.9
The voxel size of the FDG images analyzed with QPS
2012 and QGS 2012 software packages had to be magnified
by a factor of 10, as required for compatibility of small-
animal PET data with software designed for humans, as
previously described.12,13
Histologic Fluorescein Staining
A separate group of mice was sacrificed on day 2 after LAD
artery occlusion for histologic correlation of apoptosis and
[68Ga]annexin A5 uptake ex vivo (n 5 5 in the treatment
group, n 5 5 in the control group). Cervical dislocation
was performed to sacrifice the mice; prior to this, they
were anesthetized with ketamine 70 mg/kg body weight
and xylazine 15 mg/kg body weight. Hearts were excised,
rinsed with cold physiologic saline solution, and fixed by
immersion in formaldehyde (3.7%) at 4uC for a period of
24 hours. The hearts were then embedded in paraffin and
cut into 4 mm thick tissue sections, which were then
mounted on glass slides and deparaffinized.6
We employed terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL; In Situ Cell Death
Detection Kit, Roche Diagnostics GmbH, Mannheim.
Germany) to detect apoptosis. For counterstaining, we
used VECTASHIELD Mounting Medium with 49,6-
diamidin-2-phenylindol (DAPI). We then examined the
slides with fluorescence microscopy (403) at 515 to 565 nm
for counting apoptotic cells and 450 to 500 nm for counting
all counterstained cells in the field of view (FOV) as
previously described.6 Cell numbers were counted in five
FOV within the infarction. The apoptosis ratio was
calculated as the number of apoptotic cells divided by the
total number of cells in each FOV.
Statistical Analysis
All continuous variables were expressed as mean 6
standard deviation. The Kolmogorov-Smirnov test was
used to test the variables for normal distribution. The
Levene test was used to test for the equality of variances in
different samples. Paired and unpaired Student t-tests were
Figure 1. Schematic illustration of
the study protocol. Animals of the
parathyroid hormone treatment group
and animals of the control group were
imaged according to the protocol.
LAD 5 left anterior descending artery.
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used where appropriate. Regression analysis and Pearson r
were used to test for correlations between normally
distributed variables. A p value # .05 was considered
statistically significant.
Results
In Vivo Quantification of [68Ga]Annexin A5 Uptake
The mean [68Ga]annexin A5 uptake by PET was 7.4 6
1.3 %ID/g within the area at risk for the control group and
4.5 6 1.9 %ID/g for the PTH group (p 5 .013). In healthy
myocardium, [68Ga]annexin A5 uptake did not differ
significantly between the control and treatment groups
(3.6 6 1.7 versus 3.4 6 1.8 %ID/g; p 5 .849). Compared
to the healthy myocardium, the treatment group did not
show significantly different tracer uptake in the area at risk
(p 5 .375), whereas the control group showed elevated
tracer uptake in the area at risk compared to the healthy
myocardium (p , .001) (Figure 2 and Figure 3).
Histologic Fluorescein Staining
Histologic fluorescein staining in the PTH treatment
group revealed significantly fewer apoptotic cells in the
area at risk on day 2 after infarction compared to the
control group (52 6 4% vs 64 6 9%; p 5 .045) (Figure 4).
Size of Infarction and Left Ventricular Function
On day 6 after MI, both groups showed comparable infarct
sizes (26 6 11% in the control group vs 32 6 15% in the
PTH treatment group, p 5 .286). On day 30, the infarct
size increased to 27 6 12% (p 5 .105 vs day 6) in the
control group, whereas the infarct size decreased signifi-
cantly in the treatment group to 29 6 13% (p 5 .031 vs
day 6). The change in the infarct sizes from day 6 to day 30
differed significantly between groups (1 6 2% in the
Figure 2. In vivo quantification of [68Ga]annexin A5 uptake on day 2
after myocardial infarction (MI). *Significantly higher [68Ga]annexin
A5 uptake was detected in the NaCl control group compared to the
parathyroid hormone (PTH) treatment group within the MI (p 5
.013) and compared to the NaCl control group in the healthy
myocardium (p , .001) and the PTH treatment group in the healthy
myocardium (p 5 .002). **[68Ga]Annexin A5 uptake in the PTH
treatment group within the MI did not differ significantly from
annexin uptake in the NaCl control group and the PTH treatment
group within the healthy myocardium (p 5 .41 and p 5 .375,
respectively).
Figure 3. Annexin uptake and infarct size. Polar map examples of
annexin uptake on day 2 (upper row) and infarct sizes (FDG-PET) on
days 6 (middle row) and 30 (bottom row) after myocardial infarction
from the control group and the parathyroid hormone (PTH)
treatment group. In the control group example, there is maximum
annexin uptake in the anterior wall, corresponding well to the location
of the infarction (as revealed by FDG-PET on days 6 and 30), whereas
there is no discernible annexin uptake in the PTH group example
(residual annexin uptake was 1.3%ID/g in this animal). Spill-in from
the liver activity is visible in the inferior wall in both polar plots. With
regard to infarct size, there are no apparent changes in the control
group from day 6 to day 30, whereas there is a slight decrease in the
treatment group. The grid in all polar maps represents the vascular
territories (clockwise starting from above: left descending artery,
circumflex artery, and right coronary artery). The green numbers
represent the amount of infarction within the vascular territory. Slight
changes may be due to differences in the rotation of the heart. The
polar maps are normalized to the maximum tracer uptake within the
map. Thus, especially in the annexin maps, residual tracer uptake in
the healthy myocardium or in the area of infarction after PTH
treatment might not be visible. However, it was discernible by region
of interest quantification.
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control group versus 2 3 6 4% in the treatment group,
p , .010) (see Figure 3 and Figure 5).
Calculated as a marker for left ventricular function, the
LVEF was 47 6 15% on day 6 and 50 6 12% on day 30
after MI in the control group and 46 6 13% on day 6 and
47 6 13% on day 30 in the PTH treatment group. The
mean LVEFs within and between groups did not differ
significantly (p . .05).
Infarct size and LVEF showed a significant negative
correlation on days 6 and 30 in the control group (R 5
2.75, p 5 .012 and R 5 2.64, p 5 .046) as well as in the
treatment group (R 52.84, p , 0.001 and R 52.87, p ,
.001). However, there was no significant correlation
between the change in the infarct size and the change in
the LVEF from day 6 to day 30 in both groups (control
group: p 5 .239, treatment group: p 5 .820).
Discussion
In the present study, we found that treatment with PTH
significantly reduced apoptosis within the area at risk at
2 days after MI. This protection was evident to [68Ga]annexin
A5 PET, which showed an almost 40% reduction in tracer
uptake within the area at risk for the PTH group compared to
saline-treated controls. This PET finding was confirmed ex
vivo after excision and histologic examination of the hearts;
tissue from PTH-treated animals showed a significantly lower
rate of apoptosis in the TUNEL assay compared to controls.
Although we detected a slight but not significant increase in
the infarct size in the control group, the treatment group
showed a significant decrease in infarct size. The comparison
of the deltas (+1% infarct size in the control group vs 23%
infarct size in the treatment group) likewise reached statistical
significance. The salvage of this amount of myocardium was,
however, without effect on recovery of LVEF, as measured by
FDG-PET.
[68Ga]Annexin A5 Tracer Uptake on Day 2
Zaruba and colleagues showed in 2008 that PTH treatment
in a murine model of MI significantly rescued the
apoptosis rate as detected by the TUNEL assay (36% in
controls versus 19% in the treatment group).1 We likewise
found a significant reduction in the abundance of
apoptotic cells in the PTH treatment group (64% versus
52%). The higher numbers of apoptotic cells could reflect
our use of fluorescence TUNEL staining rather than the
less sensitive peroxidase staining in the Zaruba and
colleagues study. Furthermore, the treatment led to a
reduction in apoptotic cells of 12% in our study, whereas
Zaruba and colleagues detected a slightly higher reduction
of 17%.1 In contrast, our histologic examination was
confirmed by [68Ga]annexin A5 PET, which we earlier
established to measure phosphatidylserine externalization
by apoptotic and also necrotic cells within an area of
infarction.6,14 In good correlation with our own findings
from the TUNEL assay at day 2 after infarction,
[68Ga]annexin A5 uptake was significantly lower in the
PTH-treated group, indicating reduced cell death.
The reduction in apoptosis was less pronounced using the
TUNEL assay for detection compared to annexin PET. We
assume that the lesser reduction observed with fluorescein
staining might be due to two reasons. First, the method of
detecting apoptotic cells is different in both approaches.
TUNEL staining uses the detection of certain DNA fragments
that occur during apoptosis, whereas annexin A5 binds to
phosphatidylserine, which is externalized to the cell surface
Figure 4. Percentage of apoptotic cells on day 2 after myocardial
infarction (MI) in TUNEL assay. On day 2 after MI, the TUNEL assay
showed significantly fewer apoptotic cells in the parathyroid hormone
(PTH) treatment group compared to the NaCl control group (p 5
.045).
Figure 5. Change in the infarct size between days 6 and 30. FDG-PET
measurements of the infarct size increased by 1% between days 6 and
30 in the NaCl control group, whereas it decreased by 3% in the
parathyroid hormone (PTH) control group; the difference reached
statistical significance (p 5 .01).
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during apoptosis.6,15 There is a chance that PTH has slightly
different effects on the occurrence of these DNA fragments
and the externalization of phosphatidylserine, with regard
to both the amount of up- and downregulation and the
temporal changes. This might ultimately lead to different
detection rates. Different detection rates of annexin PET
and TUNEL staining were also observed in a previous article
by our group.6 Second, TUNEL staining might also be more
sensitive than annexin PET because single apoptotic cells
can be detected by TUNEL staining, whereas annexin PET
indirectly measures the amount of apoptotic cells by uptake
values. This might also explain the lesser reduction in
apoptosis as observed by TUNEL staining simply because
more apoptotic cells can be detected. Nevertheless, both
methods show good agreement with regard to the effect
of PTH.
Thus, we confirm Zaruba and colleagues’ demonstra-
tion of cardioprotective therapy monitoring and can
predict that [68Ga]annexin A5 PET should serve for
longitudinal therapy monitoring in individual animals, as
has been proposed.16–18 Since we were able to detect
therapy effects even at an early point in time, PET might
also prove useful for risk stratification. Thus, small-animal
PET with [68Ga]annexin emerges as a sensitive assay for
detection of changes in phosphatidylserine externalization,
a surrogate marker for apoptosis at day 2 after MI.
Infarct Size and LVEF
Several studies showed that PTH treatment after MI had
beneficial effects on the course of ischemic cardiomyo-
pathy.1,2,19 So-treated animals have had smaller infarct
sizes, improved LVEF, and generally better survival
rates.1,2,19 Our study agrees with the aforementioned
studies insofar as the infarct sizes increased slightly from
day 6 to day 30 in the control group while decreasing in
the treatment group (day 6 after MI compared to day 30).
The statistically not significant difference in the infarct size
at the baseline scan on day 6 (26% in the control group,
32% in the treatment group) might be due to either PTH
treatment or variations in the occlusion model. Given that
other studies did not reveal any difference in infarct size
at the baseline (as measured by histology or perfusion
scintigraphy) in control and PTH treatment groups,1,19 we
do not have any evidence that PTH might cause such a
difference. Thus, we surmise that the difference measured
in our study is most likely due to variations in the LAD
artery occlusion mouse model even though the operations
were carried out by the same experienced microsurgeon
under identical conditions.
Although the stated decrease in infarct size in the PTH
group might be partially based on the initially more
extended areas of infarction, we want to raise two points
that might amend for this. First, infarct sizes were very
extensive in both groups, comprising between a fourth and
a third of the whole left ventricular myocardium. Due to
these sizes, one might speculate that a (statistically not
significant) difference should not affect the outcome as
much as would be the case with smaller infarct sizes.
Second, more meaningful than the within-group compar-
isons of matched pairs should be the between-group
comparison of deltas because these are irrespective of the
absolute baseline and follow-up infarct sizes. The decrease
in the infarct size in the treatment group and the increase
in the infarct size in the control group are in accordance
with what would be expected of PTH treatment.2
The reduction in the infarct size with PTH treatment
(which reached statistical significance in both the within-
group comparison from day 6 to day 30 in the treatment
group and the comparison of deltas between the control
and treatment groups) might reflect improved cell
survival, decreased cell loss through the recruitment of
bone marrow progenitor cells, and increased homing of
these cells to infarcted myocardium, as has been proposed
by Brunner and colleagues.2,3
Our infarct size results are in good agreement with the
study by Huber and colleagues in 2010, who used
myocardial perfusion single-photon emission computed
tomography (SPECT) to analyze perfusion defects in a
murine model of MI in a control group and in three
treatment groups (PTH, granulocyte colony-stimulating
factor [G-CSF], and PTH + G-CSF).19 Although the
perfusion defects increased by approximately 1% between
days 6 and 30 in the control group, they decreased by up to
3% in the treatment groups. In contrast, Zaruba and
colleagues detected a far greater (14%) rescue of infarct
size in a similar model of murine infarction and PTH
treatment.1 This could be explained in part by the differing
methods of calculating infarct sizes. Whereas we delineated
infarcts on an ECG-gated FDG-PET scan relative to a
normative database, which is the standard in clinical
settings,20 Zaruba and colleagues and Deindl and collea-
gues used histologic staining for the calculation of infarct
sizes.1,21 For example, myocytes can show residual FDG
uptake in the regions of a PET scan, which might be
judged to be infarcted by histologic analysis. However, this
seems inadequate to account for the full extent of the
disagreement, that is, a 3% decrease in our study and a
14% decrease in the Zaruba and colleagues study.
Additional relevant factors may include the metabolic
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state at the time of scanning or stress through repeated
measurements as well as partial volume effects.
We expected that PTH might rescue cardiac function,
but the LVEF remained virtually unchanged between days
6 and 30, irrespective of treatment. As expected, infarct
sizes and LVEF showed a negative correlation on days 6
and 30 in both groups. However, the reduction in the
infarct size did not lead to improved left ventricular
function. This seems more consistent with the small
changes in infarct volume but less consistent with the
apoptosis findings. Zaruba and colleagues and Brunner
and colleagues both found significantly higher LVEF on
day 6 in the therapy group compared to the control group
but no further effect of PTH between days 6 and 30.1,2
Nevertheless, LVEF in the therapy group was significantly
higher during the course of the studies. Just as with infarct
sizes, the effects of PTH on LVEF might depend on various
physiologic and environmental factors. Interestingly,
above-normal PTH levels have been associated clinically
with heart failure among older people and impart a higher
risk of cardiac events in people with stable coronary heart
disease.22,23 Even though there is convincing evidence that
PTH supplementation can enhance stem cell homing,
neovascularization, and attenuation of ischemic heart
failure, it may also interfere under some circumstances
and aggravate heart failure. This might partly be reflected
in our study, where despite clearly increased cell survival,
the effects on infarct size and left ventricular function were
not as resounding as might have been expected.
Limitations
The study has several limitations that need to be addressed.
First, annexin A5 shows a high liver uptake. Given that
the liver is adjacent to the heart, especially to the inferior
wall, this could seriously hamper uptake measurements
made with this tracer. Because our main focus was on the
LAD artery perfusion territory (mostly the anterior wall),
this did not present a major problem; however, it needs to
be taken into consideration for future clinical applications,
which might necessitate measurements in the inferior wall.
Second, the infarct sizes in the control and treatment
groups showed a nonsignificant difference at the baseline
scan. As discussed above, we are of the opinion that this is
mostly due to variations in the LAD artery occlusion
model. Although we do not think that the conclusion of
this study has been thereby hampered, it still clearly shows
the limitations of this small-animal model.
Third, when analyzing the annexin uptake by placing
standardized VOI into the peak of tracer uptake, the
occurrence of partial volume effects cannot be excluded.
However, due to our standardized approach, we expect
them to introduce a systematic error, if any at all.
Conclusion
We made the first demonstration of therapy monitoring
with [68Ga]annexin PET in a small-animal model of MI.
Treatment with PTH significantly attenuated cell death on
day 2. Despite slight differences at the baseline scan, the
controls showed an increase in infarct size, whereas the
treatment group showed a decrease over the course of the
study. These differences were significant.
However, there was no beneficial effect on the functional
parameter LVEF. Our results partly confirm the cardiopro-
tective effects of PTH treatment described in preceding
animal studies but also draw attention to the ambiguous
role of PTH in cardiovascular disease, as described in
clinical settings. Further studies may better elucidate the
role of PTH in the treatment of heart disease and heart
failure and the associated molecular pathways, leading to
positive and negative effects.
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